The Councilor for Health Policies of the Emilia Romagna Region, Raffaele Donini, visited the GlaxoSmithKline (Gsk) plant in San Polo di Torrile, in the province of Parma. Today’s meeting, which was also attended by the mayor of San Polo di Torrile, Alessandro Fadda, “marks the synergy between industrial and institutional forces – underlines Gsk ibn a note – and launches an important signal of economic vitality for the territory from a production site already projected towards the future and the export of innovative drugs “. The Gsk plant in Parma – recalls the Italian arm of the British company – specializes in the introduction of new products: from the worldwide production of drug candidates for registration clinical trials, up to the large-scale one when these treatments are approved. by the drug agencies of the different countries. The industrial site also plays an important role in bioanalytical quality controls on GSK products to allow for export, and is recognized worldwide for the production of innovative monoclonal antibodies for the treatment of diseases such as lupus, severe asthma and multiple myeloma. Finally, in recent days, the plant has also distinguished itself as a center for the production of sotrovimab, a monoclonal antibody for Covid patients at risk of aggravation, which has obtained the green light from the European drug agency Ema and the American Fda for emergency use, after having demonstrated that it can avoid death or hospitalization in 85% of cases. “We were fascinated by the innovation, by the technologies present in the plant and by the passion of the people who work there – said Donini – It is an honor have a technological plant of this type in our region. As institutions we are committed to creating the best conditions to attract investments and develop the right skills “.” We specialize in sophisticated and innovative productions that require skills, workers, technologies, safety and design to higher levels – highlighted Maria Chiara Amadei, plant manager and CEO of Gsk Manufacturin g – And innovation is the driving force behind our entire business. I am pleased to be able to say that Parma is making an important contribution from this point of view within the profound technological and innovative transformation that is revolutionizing the pharmaceutical sector “.” We have two fundamental commitments that we try to respect every day “, said Fabio Landazabal, president and CEO of Gsk SpA: “Towards patients, for whom we have to develop innovative treatments and produce high quality drugs, and towards our territory, where we have to do business, prevention, innovation and exports”.